Trial · NCT02282514
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
NCT02282514, Phase 1, Phase 2, Terminated, Northwestern University; results first posted 2021-01-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stem Cell Transplantation for Stiff Person Syndrome (SPS). Trials, record NCT02282514. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02282514
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- NCT number
- NCT02282514
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 23 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Stiff-Person Syndrome
- Interventions
- Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan
- First posted
- 2014-11-04
- Last updated
- 2021-01-27
- Results first posted
- 2021-01-06
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival | Mean 3.6 years | Number of Participants who Did Not Experience Treatment-Related Mortality |
| Secondary | Reduction of Muscle Relaxation Anti-spasmatic Medications | Mean 3.6 years | Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications |
| Secondary | Short-form 36 Quality of Life Questionnaire (SF-36 QOL) | mean 3.6 years | Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival | Mean 3.6 years | participants | NUMBER | |
| SECONDARY | Reduction of Muscle Relaxation Anti-spasmatic Medications | Mean 3.6 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Short-form 36 Quality of Life Questionnaire (SF-36 QOL) | mean 3.6 years | units on a scale | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Hematopoietic Stem Cell Transplantation | 23 | participants | ||
| Reduction of Muscle Relaxation Anti-spasmatic Medications | Hematopoietic Stem Cell Transplantation | 14 | Participants | ||
| Short-form 36 Quality of Life Questionnaire (SF-36 QOL) | Hematopoietic Stem Cell Transplantation | Pre Treatment | 37.75 | Standard Deviation 12.81 | units on a scale |
| Short-form 36 Quality of Life Questionnaire (SF-36 QOL) | Hematopoietic Stem Cell Transplantation | Post Treatment | 58.35 | Standard Deviation 22.81 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hematopoietic Stem Cell Transplantation | 23 | |
| Overall Study | COMPLETED | Hematopoietic Stem Cell Transplantation | 23 | |
| Overall Study | NOT COMPLETED | Hematopoietic Stem Cell Transplantation | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Endocrine disorders | Hematopoietic Stem Cell Transplantation | 5 | 23 | 5 |
| serious | Non Treatment Related Death | General disorders | Hematopoietic Stem Cell Transplantation | 1 | 23 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hematopoietic Stem Cell Transplantation | 1 | 23 |
| Total, other adverse events | Hematopoietic Stem Cell Transplantation | 5 | 23 |
| Total, serious adverse events | Hematopoietic Stem Cell Transplantation | 1 | 23 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33318163 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02282514
GET https://conductscience.org/api/trials/v1/NCT02282514/registered